-
Mashup Score: 3The Emerging Landscape of Targeted Therapeutics for Genetic Neuromuscular Disorders - Practical Neurology - 8 month(s) ago
Advances in targeted therapeutics for neuromuscular disease have profoundly altered clinical approaches to these disorders and the use of genetic testing.
Source: practicalneurology.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0
The neuromuscular world is an exciting place to be right now. Since the time I trained as a resident and fellow, there has been a sea change in how we
Source: practicalneurology.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0Neuromuscular Disorders | Journal | ScienceDirect.com by Elsevier - 10 month(s) ago
Read the latest articles of Neuromuscular Disorders at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature
Source: www.sciencedirect.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0Wolters Kluwer Health - 10 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0Implantable Neural Interface Device Enables Patients with Neuromuscular Disorders to Communicate Using Thoughts - Practical Neurology - 11 month(s) ago
The cofounders of Synchron, Dr. Thomas Oxley and Dr. Nicholas Opie, have developed an implantable brain-computer interface (BCI), the Synchron Switch,
Source: Practical NeurologyCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 3
Scribe Therapeutics will partner with Eli Lilly subsidiary Prevail Therapeutics to develop in vivo CRISPR-based therapies for neurological and neuromuscular diseases, through an up-to-$1.5 billion collaboration.
Categories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 2
Scribe Therapeutics will partner with Eli Lilly subsidiary Prevail Therapeutics to develop in vivo CRISPR-based therapies for neurological and neuromuscular diseases, through an up-to-$1.5 billion collaboration.
Categories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0Q&A: Guideline provides better respiratory care for patients with neuromuscular diseases - 12 month(s) ago
Patients with neuromuscular diseases face an increased risk for respiratory muscle weakness, which can contribute to various health and mental problems that take a significant toll on their lives.There is limited guidance on managing respiratory muscle weakness associated with neuromuscular diseases, Akram Khan, MD, associate professor of pulmonary, allergy and critical care medicine at Oregon
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 1Myasthenia Gravis and Vision - 12 month(s) ago
Dr. Henry Kaminski, of George Washington University, explains why ophthalmologists can often be the first physicians to see a person with myasthenia gravis.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Myasthenia Gravis and Vision - 1 year(s) ago
Dr. Henry Kaminski, of George Washington University, explains why ophthalmologists can often be the first physicians to see a person with myasthenia gravis.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Defne A. Amado, MD, PhD and Ashley Robbins, BS explore the ways that emerging targeted therapeutics for neuromuscular diseases have altered clinical approaches and the use of genetic testing: https://t.co/6xmL6FDjjB #Neuromuscular #TargetedTherapeutics #NeuromuscularDisease https://t.co/CGRSBCr4Xt